Clinical Trials

An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)


Study ID
Juno Therapeutics-JCAR017

NCT Number
NCT03331198 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0395

Principle Investigator
Dr. Tatyana Feldman

Phase
I

Sponsor
Juno Therapeutics


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now